TABLE 5.
Characteristic | No. (%) of isolates among: |
|
---|---|---|
145 isolates from 120 carriers | 13 isolates from 13 long-term carriers | |
O serogroup | ||
O1 | 11 (7.5) | 3 (23.1) |
O25 | 27 (18.6) | 4 (30.8) |
O15 | 3 (2.1) | 1 (7.7) |
O74 | 5 (3.4) | 1 (7.7) |
O78 | 4 (2.8) | 1 (7.7) |
Other O serogroups | 32 (22.2) | 0 (0) |
OUT | 63 (43.4) | 3 (23.1) |
Molecular type of ESBL | ||
CTX-M-1 group | 30 (20.7) | 3 (23.1) |
CTX-M-2 group | 19 (13.1) | 0 (0) |
CTX-M-8 group | 7 (4.8) | 0 (0) |
CTX-M-9 group | 82 (56.6) | 10 (76.9) |
Non-CTX-M | 7 (4.8) | 0 (0) |
Resistance to: | ||
Ceftazidime | 25 (17.2) | 3 (23.1) |
Aztreonam | 59 (40.7) | 5 (38.5) |
Gentamicin | 34 (23.4) | 2 (15.4) |
Amikacin | 1 (0.7) | 0 (0) |
Minocycline | 96 (66.2) | 8 (61.5) |
Chloramphenicol | 23 (15.9) | 1 (7.7) |
Fosfomycin | 9 (6.2) | 0 (0) |
Ciprofloxacin | 67 (46.2) | 11 (84.6) |
Levofloxacin | 66 (45.5) | 11 (84.6) |